Have you ever looked at your investment portfolio and felt that nagging sense something just isn’t quite right? Maybe a position that once felt solid now carries a bit too much uncertainty for comfort. That’s exactly the kind of moment many thoughtful investors face when weighing opportunities in the complex world of big pharma stocks.
Recently, a notable shift happened in one prominent charitable trust’s holdings. They decided to close out their stake in Bristol Myers Squibb and start building a new position in Johnson & Johnson. On the surface, it might look like a simple exchange between two healthcare giants. But dig a little deeper, and you’ll find a story about commercial execution, pipeline potential, and strategic focus that could matter for anyone interested in the pharmaceutical sector.
Why Make a Pharmaceutical Swap Right Now?
Timing in the market is rarely perfect, but sometimes the stars align just enough to prompt action. In this case, the move came after Bristol Myers Squibb delivered a modest gain of around 3.5 percent on the remaining shares held. Not bad, but certainly not enough to justify hanging on if better opportunities appeared elsewhere. The decision wasn’t driven by panic or some sudden negative headline. Instead, it reflected a careful assessment of where each company stands today and where they might head over the coming years.
Bristol Myers Squibb had faced some headwinds earlier in the period, including concerns around potential tariffs and a disappointing result in a late-stage trial for its schizophrenia treatment candidate as an add-on therapy. While the stock recovered nicely in recent months—rallying about 30 percent as those tariff worries eased—questions remain about navigating an upcoming patent cliff. Several important clinical readouts are expected this year, each carrying that binary risk inherent in drug development.
Rather than betting everything on those specific trial outcomes, the thinking here leans toward favoring companies that demonstrate consistent commercial excellence. That’s where Johnson & Johnson enters the picture. It had been sitting on a watchlist for some time, and the longer-term performance tells an interesting tale. Over the past year, JNJ advanced roughly 58 percent compared to a more modest 10 percent for Bristol Myers Squibb. Even in the most recent six months, while Bristol Myers edged ahead slightly, the overall trajectory favored the more diversified player.
I’ve always believed that in healthcare investing, stability and execution often outweigh flashy short-term pops. Perhaps that’s why this swap feels like more than just rotating between two tickers—it’s about upgrading the quality of pharmaceutical exposure in a portfolio.
Understanding Bristol Myers Squibb’s Recent Journey
Bristol Myers Squibb remains a significant name in oncology and other therapeutic areas, with a pipeline that includes several promising candidates. The company has shown resilience, bouncing back from earlier pressures. Yet the missed trial for Cobenfy as an adjunctive treatment in schizophrenia highlighted the challenges of drug development, especially when expectations run high.
Despite that setback, the stock found support as investors looked past the immediate disappointment and focused on other assets. Milvexian, a drug being developed in partnership with another major player, represents one area of potential upside in stroke prevention and atrial fibrillation. Still, success there would likely benefit the larger partner more given the relative sizes of the companies involved.
Binary events in clinical trials can make or break near-term momentum, but sustainable value comes from consistent commercial performance across a broad portfolio.
– Healthcare investment perspective
The decision to exit wasn’t about declaring the company a failure. Far from it. Bristol Myers Squibb still holds interesting assets and could deliver positive surprises with upcoming data. But when comparing risk-reward profiles side by side, another option started looking more compelling for the long haul.
Johnson & Johnson: A Tale of Diversification and Focus
Johnson & Johnson presents a different profile altogether. With approximately $94 billion in sales last year, the company splits its business roughly two-thirds in innovative medicines (pharmaceuticals) and one-third in medical devices and products, often referred to as the MedTech segment. This balance provides a natural hedge that pure-play pharma companies sometimes lack.
The innovative medicines division grew 5.3 percent year-over-year, powered by double-digit increases in 13 different brands. Oncology stands out as a particular strength, generating about $25 billion in revenue with ambitious plans to exceed $50 billion annually by 2030. Drugs like Darzalex, Tecvayli, and Carvykti form a formidable presence in multiple myeloma, while other areas such as immunology (think Tremfya) and neuroscience continue to gain traction.
On the MedTech side, revenue rose 5.4 percent, with key contributions from cardiovascular, surgery, and vision products. This diversified revenue stream helps smooth out the inevitable bumps that come with patent expirations or clinical trial outcomes in any single therapeutic area.
- Oncology franchise targeting substantial long-term expansion
- Strong immunology portfolio with multiple growth drivers
- MedTech business providing stability and additional upside
- Neuroscience strengthened through strategic moves
What really caught attention recently was Johnson & Johnson’s acquisition of Intra-Cellular Therapies for about $14.6 billion. This brought Caplyta into the fold—a drug already approved for schizophrenia and bipolar depression, with its label later expanded to include major depressive disorder. In an interesting twist, this asset positions Johnson & Johnson as a potential competitor in the same space where Bristol Myers Squibb had faced challenges with its own candidate.
The Icotyde Breakthrough and Competitive Edge
One of the more exciting recent developments involves Icotyde, an oral IL-23 receptor antagonist approved by the FDA for moderate-to-severe plaque psoriasis in adults and children as young as 12. Being the first oral treatment of its kind in this category gives Johnson & Johnson a meaningful advantage over existing options.
Before approval, head-to-head studies showed Icotyde delivering better skin clearance than certain competing oral therapies that work through different mechanisms. This could allow it to capture share not only from other orals but potentially even from injectable treatments that dominate the market today. For patients tired of injections, an effective once-daily pill represents a genuine quality-of-life improvement.
In my experience following healthcare innovations, breakthroughs that combine efficacy with convenience often reshape treatment paradigms faster than many analysts initially expect. Icotyde seems to fit that profile, and its success could bolster Johnson & Johnson’s already impressive immunology franchise.
The shift toward oral therapies in autoimmune conditions reflects both scientific progress and patient preferences for less invasive options.
Meanwhile, the partnership on Milvexian means Johnson & Johnson still stands to benefit from positive developments in that program, even if the larger impact accrues to its partner. It’s a nice complementary exposure without over-reliance on any single outcome.
Portfolio Transformation: Shedding the Old to Embrace the New
Johnson & Johnson hasn’t stood still. Back in 2023, the company spun off its consumer health business—home to familiar names like Tylenol and Band-Aid—into what became Kenvue. At first, the move took time to win over investors, but eventually it allowed the core business to trade at a higher valuation multiple as the market rewarded greater focus on higher-growth, higher-margin segments.
More recently, in October of last year, management announced plans to separate the orthopaedics business known as DePuy Synthes. The goal remains sharpening focus on faster-growing areas within MedTech, such as cardiovascular and vision. Whether this separation ultimately happens through a spin-off or a sale (rumors have circulated about private equity interest potentially reaching $20 billion), the strategic intent is clear: streamline operations to drive better top-line growth and improved margins.
Management believes this will lead to another positive re-rating of the company’s price-to-earnings multiple. With the target completion window set at 18 to 24 months from announcement, there’s still time for the market to digest the implications fully.
Addressing Lingering Legal Concerns
No discussion of Johnson & Johnson would be complete without mentioning the long-running baby powder litigation. When the company was previously held in certain portfolios a couple of years ago, these legal issues created ongoing volatility. Headlines could move the stock dramatically depending on courtroom outcomes.
Thankfully, the situation appears to have de-escalated. By shifting strategy toward defending cases individually rather than pursuing broad settlements, the company has reduced the overhang. While occasional losses still occur, the stock no longer seems hostage to every single development in the courtroom. This normalization of risk represents another quiet positive for long-term holders.
It’s a reminder that even the strongest companies face challenges. What matters is how management navigates them and whether the core business remains fundamentally sound. In Johnson & Johnson’s case, the operational momentum seems to have largely moved past this chapter.
Breaking Down the Trade Mechanics
The specifics of the transaction provide additional context. The exit from Bristol Myers Squibb involved selling 1,100 shares at approximately $58.94. On the buy side, 150 shares of Johnson & Johnson were purchased at roughly $237.65. After the trades, the portfolio holds no remaining Bristol Myers Squibb and about 150 shares of Johnson & Johnson, representing roughly 1 percent of total assets.
Notice the deliberate sizing. The sale generated more cash than was immediately deployed into the new position. This leaves flexibility to add to Johnson & Johnson over time, particularly around upcoming earnings reports where volatility might create attractive entry points. It also allows the portfolio to capture some extra liquidity during a relief rally in the broader market.
| Action | Shares | Approximate Price | Impact |
| Sell Bristol Myers Squibb | 1,100 | $58.94 | Exit full position, realize small gain |
| Buy Johnson & Johnson | 150 | $237.65 | Initiate ~1% portfolio weight |
A price target of $265 was set for the new Johnson & Johnson position. This implies roughly 23 times the midpoint of expected 2026 adjusted earnings per share—a level that many would consider reasonable given the company’s quality and growth prospects.
Broader Context: What This Means for Pharma Investors
This isn’t just one isolated trade. It reflects broader themes playing out across the healthcare sector. Patent cliffs remain a constant concern for companies with blockbuster drugs losing exclusivity. Those that invest wisely in new innovations and manage their portfolios proactively tend to fare better over time.
Johnson & Johnson’s emphasis on oncology expansion, combined with moves in immunology and neuroscience, positions it to benefit from several secular trends in medicine. Aging populations, advances in targeted therapies, and growing demand for treatments in mental health all play into this narrative.
Meanwhile, the MedTech business benefits from procedural volume recovery and innovation in areas like robotics and minimally invasive techniques. Having both pharmaceutical and device exposure under one roof creates synergies that pure-play competitors might envy.
- Diversified revenue streams reduce single-product risk
- Proven ability to execute spin-offs and focus strategies
- Strong balance sheet supporting both organic growth and acquisitions
- Track record of navigating legal and regulatory challenges
- Clear roadmap for multiple therapeutic areas with high unmet need
Of course, no investment is without risks. Johnson & Johnson still faces competition in crowded fields like oncology and immunology. Pricing pressures in the U.S. healthcare system remain a perennial concern. And while the orthopaedics separation aims to unlock value, execution risk always exists with complex corporate restructurings.
Yet when weighing these factors against the alternative of staying fully exposed to Bristol Myers Squibb’s more concentrated risks around its patent cliff and clinical catalysts, the swap starts making intuitive sense. It’s less about being bearish on one name and more about being selectively bullish on the other.
Thinking About Your Own Portfolio Decisions
If you’re an individual investor following big pharma, this example raises some useful questions. How much concentration risk are you willing to accept in your healthcare holdings? Do you prefer betting on specific clinical catalysts or backing companies with broader commercial engines? How do you evaluate the impact of corporate portfolio transformations?
There’s no universal right answer—these decisions depend on your time horizon, risk tolerance, and overall asset allocation. But studying moves like this one can help sharpen your own thinking. Sometimes the most powerful action isn’t chasing the hottest story but quietly upgrading to higher-quality exposure when the opportunity arises.
In my view, Johnson & Johnson’s combination of diversified growth drivers, strategic focus, and improving risk profile makes it an attractive holding for those seeking more durable pharmaceutical exposure. The fact that it had been monitored on a watchlist for some time before initiating suggests the decision wasn’t rushed but rather the result of patient observation.
Looking Ahead: What to Watch For
For Johnson & Johnson, key upcoming catalysts include continued execution on the oncology expansion targets, progress with Icotyde in the real-world setting, and any further updates on the orthopaedics separation timeline. Earnings reports will provide important color on sales trends across franchises.
Investors will also want to monitor how the neuroscience portfolio, now bolstered by the Caplyta addition, performs in an increasingly competitive mental health treatment landscape. Early signs from label expansions appear encouraging, but commercial uptake always takes time to prove out.
On the Bristol Myers Squibb side, those following the name will focus on the various pipeline readouts mentioned earlier. Success in any of the key programs could reignite momentum, while setbacks might pressure the valuation further as the patent cliff approaches.
Beyond the individual companies, broader sector dynamics—such as potential policy changes around drug pricing, innovation incentives, and merger and acquisition activity—will influence performance across the board. Geopolitical factors, including any renewed tariff discussions, could also resurface as points of volatility.
Successful healthcare investing often rewards patience and a focus on fundamental business quality over short-term noise.
Ultimately, this pharmaceutical swap highlights how even sophisticated investors continuously evaluate their holdings against alternatives. Small adjustments, when made thoughtfully, can compound into meaningful differences over time.
Whether you’re managing a large portfolio or simply your own retirement accounts, keeping an eye on how industry leaders position themselves for the future remains valuable. Companies that demonstrate both innovation and operational discipline tend to create the most sustainable shareholder value.
As always, this type of discussion serves an educational purpose rather than constituting specific investment advice. Individual circumstances vary widely, and professional guidance tailored to your situation is essential before making any portfolio changes.
The world of pharmaceutical investing never stands still. New therapies emerge, competitive landscapes shift, and corporate strategies evolve. By examining moves like the recent exit from one name and entry into another, we gain insight into the factors that professional investors weigh when making decisions. In this case, the emphasis on commercial excellence, diversified growth, and proactive portfolio management appears to have tipped the scales.
Johnson & Johnson’s recent performance, strategic actions, and pipeline developments suggest it could offer a more resilient path forward compared to the higher binary risks associated with Bristol Myers Squibb at this juncture. Of course, only time will tell how both companies fare, but the rationale behind upgrading exposure makes for a compelling case study in thoughtful healthcare investing.
What do you think—does diversification within healthcare appeal to you more than concentrated bets on specific drugs? Have you ever made a similar swap in your own portfolio when one opportunity started looking clearly better than another? Sharing experiences (without specific recommendations, of course) can help all of us become more informed investors over time.
Stay tuned to developments in both companies and the broader sector. The pharmaceutical industry continues to deliver remarkable advances in treating serious conditions, and identifying the best ways to participate as investors remains both challenging and rewarding.
